Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2019 · Journal of Clinical Oncology · 276 citations
https://doi.org/10.1200/jco.19.00066
L
Lauren L. Ritterhouse
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
160
Papers
6.4K
Citations
34
h-index
69
i10-index
Lauren L. Ritterhouse is an academic researcher from Boston Foundation. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Lung Cancer Treatments and Mutations & Ovarian cancer diagnosis and treatment. The author has an h-index of 34, co-authored 136 publications.
ORCID: 0000-0002-7655-630XPapers by this author
worksCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
2024 · Nature · 123 citations
https://doi.org/10.1038/s41586-024-07943-7
Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas
2016 · Modern Pathology · 42 citations
https://doi.org/10.1038/modpathol.2016.82
ERBB2 (HER2) Alterations in Colorectal Cancer
2022 · Journal of Molecular Diagnostics · 15 citations
https://doi.org/10.1016/j.jmoldx.2022.07.001
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma
2024 · Nature Communications · 14 citations
https://doi.org/10.1038/s41467-024-51271-3
Prognostic biomarkers for survival in mucosal melanoma
2023 · Pigment Cell & Melanoma Research · 6 citations
https://doi.org/10.1111/pcmr.13104
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat